Clinical Trials Logo

Clinical Trial Summary

We hypothesize that transcranial direct current stimulation will reduce tobacco withdrawal symptoms of tobacco dependent smokers abstinent from smoking for more than 10 hours.


Clinical Trial Description

We will recruit 35 non-smokers and 30 adult smokers who smoke > 15 cigarettes/day for more than two years and are 18-55 years old. We expect about half of them will be females. All participants will be screened for drugs of abuse and female participants will receive a pregnancy test. Each smoker will participate in four tDCS sessions, one for sham and three for real tDCS, each for one set of electrode montage. The first set is dorsal lateral prefrontal cortex (i.e., F3 and F4 of 10/20 EEG system) and neck. The second set is middle line prefrontal cortex (Fz), superior parietal cortex (Pz), and bilateral inferior temporal cortex (T3 and T4). The third set is left dorsal lateral prefrontal cortex (F3) and superior parietal cortex (P1), and right inferior temporal cortex (T4). The sequence of real and sham tDCS will be counterbalanced among participants. Each session will last for 20 minutes and there will be a minimum 48 hours between the two sessions. Participants will be required to be abstinent from cigarette smoking overnight for a minimum of 10 hours and arrive at our lab around 8:30 AM for each tDCS session. After arrival, each participant will provide a breath sample for detection of any alcohol in their system, an assay of CO and for verification of abstinence from cigarette smoking. We will place a nicotine patch (Nicoderm with 21 mg nicotine) on the back of participants. We will also ask each participant to chew a nicotine gum (Nicorette gum with 4 mg nicotine) for 30 minutes. The participants will perform a battery of computerized tasks including the N-Back working memory task, and an attention task involving watching a computer screen and pressing buttons to indicate more odd or even numbers displayed on the screen. In addition participants will complete the following questionnaires related to mood, nicotine withdrawal, mental state, possible side effects, and cigarette craving: Profile of Mood States (McNair et al 1971), Shiffman-Jarvik Withdrawal Scales (Shiffman & Jarvik 1976), and Urge To Smoke (Jarvik et al 2000), tDCS side effects questionnaire, Wisconsin Smoking Withdrawal Scale (Welsch 1999), Perceived Stress Scale (Cohen 1983), Spielberger State/Trait Anxiety Questionnaire (Spielberger 1970).

Each participant will repeat above battery of cognitive tasks and questionnaires after tDCS. Then they will be instructed to smoke one cigarette after this second battery of tasks/questionnaires, and repeat the second battery of questionnaires after cigarette smoking. ;


Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science


Related Conditions & MeSH terms


NCT number NCT01567982
Study type Interventional
Source Yale University
Contact
Status Completed
Phase Phase 1
Start date March 2011
Completion date July 2015

See also
  Status Clinical Trial Phase
Terminated NCT03840694 - Nicotine Withdrawal and Reward Processing: Connecting Neurobiology to Real-world Behavior N/A
Recruiting NCT04429568 - THC Crossover Study N/A
Terminated NCT01492322 - SPECT Imaging of DAT Genotype Phase 1
Completed NCT01954966 - Progesterone and Brain Imaging Study Phase 4
Completed NCT00749658 - Human Laboratory Study of Varenicline and Bupropion for Nicotine Dependence Phase 2/Phase 3
Completed NCT01414998 - Sensorimotor Replacement With Electronic and De-nicotinised Cigarettes N/A
Completed NCT05041959 - Nicotine Withdrawal and Reward Processing N/A
Recruiting NCT05335915 - Acute Pharmacokinetic and Pharmacodynamic Effects of "Tobacco-Free" Oral Nicotine Pouches in Smokers Phase 1
Recruiting NCT06254001 - Effectiveness of Combined Tobacco Treatment in Hospitalized Subjects Phase 4
Recruiting NCT05513872 - Overcoming Nicotine Dependence to Enable Quitting Phase 1/Phase 2
Completed NCT01204723 - Medications Development for the Treatment of Cannabis Related Disorders Phase 1
Withdrawn NCT03473483 - Cigarette Harm Reduction With Electronic Cigarette Use N/A
Active, not recruiting NCT04163081 - The INITIATE Study: Initiating Nicotine Dependence Treatment for Smokers Admitted to Emergency Departments N/A